These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group.
    Author: Smith IE.
    Journal: Eur J Cancer; 1990; 26 Suppl 1():S19-23. PubMed ID: 2169780.
    Abstract:
    The efficacy and safety of a novel anti-emetic, granisetron, was assessed at two dose levels (40 micrograms/kg; n = 223 and 160 micrograms/kg; n = 220) in a double-blind study in 443 patients undergoing treatment with a range of standard cytostatic therapies of which cyclophosphamide was the primary emetogenic agent for most patients. In the first 24 h, 76% of patients in the lower-dose group and 81% in the higher, experienced no vomiting and no, or only mild nausea (a complete response). Two additional doses of granisetron (40 microns/kg) were allowed on the first day to treat any symptoms of nausea and vomiting. This produced improvement or resolution of symptoms in 82% to 95% of patients. Over the 7 days of the study a complete response was maintained by 40% and 42% of patients, respectively. No differences in efficacy or safety between the two doses of granisetron were established. The commonest adverse event was headache, occurring in about 15% of patients. No extrapyramidal effects were observed. There was no relationship between the total dose and the number and severity of specific adverse events.
    [Abstract] [Full Text] [Related] [New Search]